anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, endocrinology, therapy, pharmacy. SUBSTANCE: invention relates to treatment of states associated with obesity. Invention proposes to use the combined effect of sibutramine and orlistat, in particular, as a pharmaceutical composition. Invention provides additional synergetic effect in treatment in attainment of the constant value of body mass loss and reducing adverse effect of therapy. EFFECT: valuable medicinal properties of treatment and composition. 4 cl, 2 tbl
There is growing concern about the concept that exposure to environmental chemicals may be contributing to the obesity epidemic. However, there is no consensus on the obesogenic effects of emerging contaminants from a toxicological and environmental perspective. The potential human exposure and experimental evidence for obesogenic effects of emerging contaminants need to be systematically discussed. The main objective of this review is to provide recommendations for further subsequent policy development following a critical analysis of the literature for humans and experimental animals exposed to emerging contaminants. This article reviews human exposure to emerging contaminants (with a focus on antimicrobials, preservatives, water and oil repellents, flame retardants, antibiotics and bisphenols) and the impact of emerging contaminants on obesity. These emerging contaminants have been widely detected in human biological samples. Epidemiological studies provide evidence linking exposure to emerging contaminants to the risks of obesity in humans. Studies based on animal models and adipose cells show the obesogenic effects of emerging contaminants and identify modes of action by which contaminants may induce changes in body fat accumulation and lipid metabolic homeostasis. Some knowledge gaps in this area and future directions for further investigation are discussed.
BACKGROUND: Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12-17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.
METHODS: In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and BMI less than 31·5 kg/m2 and had been on stable ART for at least 90 consecutive days with an HIV-1 viral load of less than 50 copies per mL at a participating IMPAACT study site. Participants had to be willing to continue their pre-study ART during cohort 1. The primary objectives of the study were to confirm doses for oral and injectable cabotegravir and for injectable rilpivirine in adolescents living with HIV. This analysis of participant-reported outcomes included a face scale assessment of pain at each injection and a Pediatric Quality of Life Inventory (PedsQL) at baseline and week 16 for participants in the USA, South Africa, Botswana, and Thailand. A subset of 11 adolescents and 11 parents or caregivers in the USA underwent in-depth interviews after receipt of one or two injections. This trial is registered at ClinicalTrials.gov, NCT03497676.
FINDINGS: Between March 19, 2019, and Nov 25, 2021, 55 participants were enrolled into cohort 1. Using the six-point face scale, 43 (83%) of participants at week 4 and 38 (73%) at week 8 reported that the injection caused "no hurt" or "hurts little bit", while only a single (2%) participant for each week rated the pain as one of the two highest pain levels. Quality of life was not diminished by the addition of one injectable antiretroviral. In-depth interviews revealed that parents and caregivers in the USA frequently had more hesitancy than adolescents about use of long-acting formulations, but parental acceptance was higher after their children received injections.
INTERPRETATION: High acceptability and tolerability of long-acting cabotegravir or rilpivirine injections suggests that these are likely to be favoured treatment options for some adolescents living with HIV.
FUNDING: National Institutes of Health and ViiV Healthcare.
Patients receive Western ginseng PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity.
In cases of a very narrow ridge, One of the augmentation protocols is alveolar ridge-splitting techniques (RST) or alveolar ridge expansion techniques with simultaneous implant insertion. The piezoelectric surgical devices implemented for conducting bone osteotomy through the use of micrometric ultrasonic vibrations have been widely used in recent years in maxillofacial surgery. Its biggest advantages are that it allows for cutting with micrometric sensitivity while cutting hard tissues, it offers a clear vision of the surgical site due to its cavitation effect, it does not cause any damage to the soft tissues while performing these cuts, and that the bone tissue heals more quickly and seamlessly, after the cuts made by piezosurgery device. The fully synthetic bone substitute, NanoBone® (Artoss, Rostock, Germany), which will be applied in this clinical study, is basically a nanocrystalline hydroxyapatite embedded in a silica gel matrix, achieved by means of specific sol-gel techniques. Features such as interconnecting pores on the nanoscale, the open SiOH or SiO groups of polysilicic acid, its large internal surface, and the high porosity of this biomaterial are all related to the calcification processes observed within the implantation bed. While the HA component is responsible for NanoBone osteoconductive properties, the silica component is believed to induce connective tissue formation, osteoblast proliferation, bone matrix mineralization, and calcification, thus combining osteoconductive and osteoinductive properties. This phenomenon is associated with the rearrangement of the silica matrix, which could be observed in vivo.
Chronic liver inflammation, a pervasive global health issue, results in millions of annual deaths due to its progression from fibrosis to the more severe forms of cirrhosis and hepatocellular carcinoma (HCC). This insidious condition stems from diverse factors such as obesity, genetic conditions, alcohol abuse, viral infections, autoimmune diseases, and toxic accumulation, manifesting as chronic liver diseases (CLDs) such as metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), viral hepatitis, drug-induced liver injury, and autoimmune hepatitis. Late detection of CLDs necessitates effective treatments to inhibit and potentially reverse disease progression. However, current therapies exhibit limitations in consistency and safety. A potential breakthrough lies in nanoparticle-based drug delivery strategies, offering targeted delivery to specific liver cell types, such as hepatocytes, Kupffer cells, and hepatic stellate cells. This review explores molecular targets for CLD treatment, ongoing clinical trials, recent advances in nanoparticle-based drug delivery, and the future outlook of this research field. Early intervention is crucial for chronic liver disease. Having a comprehensive understanding of current treatments, molecular biomarkers and novel nanoparticle-based drug delivery strategies can have enormous impact in guiding future strategies for the prevention and treatment of CLDs.
Ischemia/reperfusion (IR)-induced acute lung injury (ALI) has a high mortality rate. Reactive oxygen species (ROS) play a crucial role in causing cellular damage and death in IR-induced ALI. In this work, we developed a biomimetic lung-targeting nanoparticle (PC@MB) as an antioxidative lung protector for treating IR-induced ALI. PC@MBs showed excellent ROS scavenging and Nrf2 activation properties, along with a lung-targeting function through autologous cell membrane coating. The PC@MBs exhibited an impressive antioxidative and pulmonary protective role via redox homeostasis recovery through Nrf2 and heme oxygenase-1 activation. PC@MBs could maintain cell viability by effectively scavenging the intracellular ROS and restoring the redox equilibrium in the lesion. In the IR mouse model, the PC@MBs preferentially accumulated in the lung and distinctly repaired the pneumonic damage. Our strategy has the potential to offer a promising therapeutic paradigm for treating IR-induced ALI through the incorporation of different therapeutic mechanisms.
Dicyclomine hydrochloride is contraindicated in women who are breastfeeding. Dicyclomine hydrochloride is excreted in breastmilk. Because of the potential for serious adverse reactions in breastfed infants from dicyclomine hydrochloride, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [see Error! Hyperlink reference not valid. (Error! Hyperlink reference not valid.)].
The present invention relates to an elongate carrier with microdepressions containing finely divided powder. The elongate carrier is formed by providing a web comprising a plurality of microdepressions in a major surface of the web. The microdepressions have a depth of about 5 to 500 microns but less than the thickness of the web and an opening at the surface of the web of about 10 to 500 microns in width and continuously feeding the web to and through a powder filling stage. At the powder filling stage, filling the powder into the microdepressions on the surface of the web is performed by using a driven roller, wherein the roller is rotating about an axis generally transverse to the direction of web movement, while the surface speed of the roller and the web speed are different and wherein the roller and web are positioned relative to one another, such that between the upper surface of the web and the outer surface of the roller there is a gap. From the surface of the web excess powder not filled within the microdepressions and remaining on areas of the surface between the depressions is removed. Subsequently, the web is optionally slit and/or cut in predetermined widths and/or predetermined lengths. The powder is fed either onto the web upstream of the roller of the powder filling stage or to the roller of the powder filling stage and comprises a biologically active substance and the biologically active substance is suitable for administration by inhalation.
Azithromycin for oral suspension, USP after constitution contains a cherry, banana and vanilla flavored suspension. The dry powder before constitution is white to off-white. The suspension after constitution is pink in color. Azithromycin for oral suspension, USP is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles as follows:

[see Dosage and Administration (2)] for constitution instructions with each bottle type.

Storage: Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Store constituted suspension between 5° to 30°C (41° to 86°F) and discard when full dosing is completed.
BACKGROUND: Early video-assisted thoracoscopic surgery (VATS) is the recommended treatment of choice for retained hemothorax (RH). A prospective single-center randomized control study was conducted to compare outcomes between VATS and thoracostomy tube (TT) reinsertion for patients with RH after penetrating trauma in a resource constrained unit. Our hypothesis was that patients with a RH receiving VATS instead of TT reinsertion would have a shorter hospital stay and lesser complications.
MATERIALS AND METHODS: From January 2014 to November 2019, stable patients with thoracic penetrating trauma complicated with retained hemothoraces were randomized to either VATS or TT reinsertion. The outcomes were length of hospital stay (LOS) and complications.
RESULTS: Out of the 77 patients assessed for eligibility, 65 patients were randomized and 62 analyzed: 30 in the VATS arm and 32 in the TT reinsertion arm. Demographics and mechanisms of injury were comparable between the two arms. Length of hospital stay was: preprocedure: VATS 6.8 (+/-2.8) days and TT 6.6 (+/- 2.4) days (p = 0.932) and postprocedure: VATS 5.1 (+/-2.3) days, TT 7.1 (+/-6.3) days (p = 0.459), total LOS VATS 12 (+/- 3.9) days, and TT 14.4 (+/-7) days (p = 0.224). The TT arm had 15 complications compared to the VATS arm of four (p = 0.004). There were two additional procedures in the VATS arm and 10 in the TT arm (p = 0.014).
CONCLUSION: VATS proved to be the better treatment modality for RH with fewer complications and less need of additional procedures, while the LOS between the two groups was not statistically different.
The present invention relates to a pharmaceutical composition for adipocyte differentiation induction and/or adipose tissue regeneration comprising, as an active ingredient, an exosome extracted from a stem cell which is differentiating into an adipocyte. The exosome is excellent in expression rate of bioactive factors influencing the differentiation into an adipocyte and has the effect of differentiating a stem cell into an adipocyte. Accordingly, the present invention can be applied to differentiation inducing agents of a stem cell, injections for tissue regeneration, fillers for cosmetic purposes, preparations for tissue engineering, etc. The invention also relates to a cosmetic composition for skin whitening, wrinkle improvement and regeneration, containing an exosome extracted from a stem cell as an active ingredient. Since the exosome contains genes, proteins, growth factors etc. associated with the proliferation, differentiation, and regeneration of stem cells; is a purified component that does not include antibiotics, serums or culture solution harmful factors; and is a cell-derived lipid transporter, the exosome can be applied to functional cosmetic compositions having skin whitening, wrinkle improvement and skin regeneration functions and scar improving preparations for cosmetic purposes, etc.
This work aimed at formulating a trilaminate dressing loaded with tranexamic acid. It consisted of a layer of 3 % sodium hyaluronate to initiate hemostasis. It was followed by a mixed porous layer of 5 % polyvinyl alcohol and 2 % kappa-carrageenan. This layer acted as a drug reservoir that controlled its release. The third layer was 5 % ethyl cellulose backing layer for unidirectional release of tranexamic acid towards the wound. The 3 layers were physically crosslinked by hydrogen bonding as confirmed by Infrared spectroscopy. Swelling and release studies were performed, and results proposed that increasing number of layers decreased swelling properties and sustained release of tranexamic acid for 8 h. In vitro blood coagulation study was performed using human blood and showed that the dressing significantly decreased coagulation time by 70.5 % compared to the negative control. In vivo hemostatic activity was evaluated using tail amputation model in Wistar rats. Statistical analysis showed the dressing could stop bleeding in a punctured artery of the rat tail faster than the negative control by 59 %. Cranial bone defect model in New Zealand rabbits was performed to check for bone hemostasis and showed significant decrease in the hemostatic time by 80 % compared to the control.
Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon MP in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
The device for storing and removing viscous paste, exhibits a main part (1) with a trough (4) for receiving a paste string (5), covers (2, 3) attached on the main part. The cover covers the string of the paste and is movable into a position, in which an end of the string is exposed for the dental purpose. The device and the trough are formed a circle. The first cover is revolvingly mounted on the main part and shows an opening in the area of the trough. The second cover is revolvingly mounted on the first cover and shows an opening that is oriented with the first cover opening. The device for storing and removing of viscous paste, exhibits a main part (1) with a trough (4) for receiving a paste string (5), a first cover (2) attached on the main part. The cover covers the string of the past and is movable into a position, in which an end of the string is exposed for the dental purpose. The device and the trough are formed a circle. The first cover is revolvingly mounted on the main part and shows an opening in the area of the trough. A second cover is revolvingly mounted on the first cover and shows an opening that is oriented with the first cover opening. The trough and the openings are arranged in the circumference area of the device. The cover with a mounting is accommodated through the rotation of the second cover, which is transferred to the first cover. The first cover is accommodated in the area of opening with a ramp that is terminated in the string end. A retaining surface for the string is arranged in the area of first cover opening on the string end. The openings of the covers are overlapped with one another. The main part with the circular trough shows a chamber (6) for receiving capsules. The second cover is accommodated in the area of the chamber with sector shaped opening that is arranged in an element revolving around the axis of the second cover. The main part and the covers are transparent and consist of plastic and a material that is impermeable for blue- and ultraviolet light. The interior of the first cover is coated with a friction reducing material.
It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
The invention relates in part to molecular complexes for delivering macromolecules (e.g., nucleic acid molecules) into cells. These molecular complexes can comprise lipophilic peptides that condense and stabilize the macromolecule. These lipophilic binding peptides can also comprise moieties that target the macromolecule to specific cells in an organism. In addition, the molecular complexes can comprise lipophilic peptides that can lyse endosomal structures within cells and thereby enhance delivery of the macromolecule into cells. The invention also relates in part to methods of delivering macromolecules to cells using the molecular complexes described herein. Thus, the present invention provides for efficient and specific delivery of nucleic acid molecules into cells.
Superior hypogastric plexus block is a kind of sympathetic plexus block which are used to control the pelvic pain caused by malignancy or other chronic condition. Classic posterior approach for this procedure is inserting the block needle at L4 -5 level and proceed the needle 45 degrees medially and 30 degrees caudally to reach the target of anterolateral space of L5 - S1 intervertebral space. Waldman et al. introduced a different angle of 30 degrees medial and caudal with the same approach, while Stevens et al. recommended 15 degrees medial and 20 degrees caudal. As such, the recommended angle for this procedure is different among references, and there is a need for suggesting a more accurate entry angle for this procedure. Therefore, we are trying to evaluate the entry angle for superior hypogastric plexus block by measuring these angle on the computed tomography image and apply these angle to the real patients.
In patients with mild (Child-Pugh 5 - 6) and moderate (Child-Pugh 7 - 9) hepatic impairment, exposure to phentermine was higher compared to healthy volunteers with normal hepatic function. Exposure to topiramate was similar among patients with mild and moderate hepatic impairment and healthy volunteers.

The recommended dosage of QSYMIA in patients with mild hepatic impairment (Child-Pugh 5 - 6) is the same as the recommended dosage in patients with normal hepatic function.

In patients with moderate hepatic impairment, the maximum recommended dosage is QSYMIA 7.5 mg/46 mg once daily.

QSYMIA has not been studied in patients with severe hepatic impairment (Child-Pugh score 10 - 15). Avoid QSYMIA in this patient population [see Dosage and Administration (2.5)and Clinical Pharmacology (12.3)] .
Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR \> 0.80.
The investigators will evaluate the feasibility and safety of administering psilocybin to 10 patients diagnosed with AUD. Following informed consent, patients will be screened for eligibility as per in- and exclusion criteria and baseline values will be recorded as per outcome measures. All patients will receive a single administration of 25 mg of psilocybin. As per safety guidelines patients will be monitored the entire dosing session by study staff familiar with the psychedelic effects of psilocybin. In addition, the patients will meet before and after the dosing session with a psychologist connected to the study for preparation and post-session debriefing, respectively. During dosing session, the investigators will collect blood plasma psilocin levels in order to establish pharmacokinetics and an estimated brain 5-HT2AR occupancy. When the effects of psilocybin subside, the investigators will ask the patients to fill out questionnaires encapsulating the psychedelic experience. One week after drug administration the patients are required to meet for an end-of-study assessment of outcome measures including adverse events.
The invention discloses a vitamin B6 gastric floating tablet which is prepared by coating a plain tablet. The plain tablet consists of the following raw materials in parts by weight: 10 parts of vitamin B6, 20 parts of framework material, 15-30 parts of bleaching agent, 9 parts of gas generating agent, 5-20 parts of filling agent and 2 parts of lubricant; wherein, the framework material is the combination of HPMC E15LV and HPMC K100LV, and the weight ratio of the combination is 1:3. Also discloses a preparation method of the vitamin B6 gastric floating tablet. The vitamin B6 gastric floating tablet has good slow release effect, active ingredients are released slowly at a constant speed, and in-vitro tests show that the tablet has slow release characteristics. The bleaching aid is used as an erosion type slow-release framework material at the same time, so that the drug rate is effectively controlled, and the slow and constant-speed release is achieved. The invention adopts an effervescent mechanism, and can quickly float in solution, and the float time is less than 5min.